AtaiBeckley Inc. (NASDAQ:ATAI) saw its shares close Monday at $7.19, representing a 44-cent premium over the $6.75 cash bid from Eli Lilly and Co. (NYSE:LLY). The close came after the Nasdaq regular session, with the day's trading reflecting the market's assessment of the contingent value rights (CVR) tied to the acquisition.
The first undiscounted projection values the contingent milestone payments at $0.44 per share, which accounts for 17.6% of the total potential $2.50 in milestone payments. This figure is below the $0.50 minimum benchmark, factoring in closure risk and extended uncertainties related to clinical developments.
The CVR, which is not listed on any exchange, includes three milestone payments linked to clinical or regulatory achievements. The final milestone spans seven years after the deal closes. The structure splits the total consideration into a $6.75 cash payment at closing and up to $2.50 in additional milestone payments per share.
Market Reaction and Trading Activity
On Monday, AtaiBeckley shares slipped 0.4%, while the broader SPDR S&P Biotech ETF (NYSEARCA:XBI) lost 2.2%. Compass Pathways plc (NASDAQ:CMPS) fell 5.5%. The prior week saw a sharper increase, with AtaiBeckley climbing 39.7% for the week ending July 17, including a 33.4% gain on Thursday alone.
Trading volumes decreased significantly on Monday, with 22.3 million shares traded, down about 87% from Thursday's 166 million shares. This drop suggests a cooling of speculative interest following the initial surge.
Analyst Actions and Milestone Details
Analysts adjusted their ratings on Monday. H.C. Wainwright's Patrick Trucchio downgraded ATAI to Neutral with a $7.50 price target, while Berenberg downgraded the stock to Hold with a $7.45 target. These moves bring analyst expectations closer to the current trading level.
The contingent milestone payments include: $1.00 per share upon beginning Phase 3 of VLS-01 (up to four years post-closing), $0.50 per share upon U.S. approval and DEA rescheduling of BPL-003 (up to five years), and another $1.00 per share upon U.S. approval and DEA rescheduling of VLS-01 (up to seven years). The merger filing on July 16 set these deadlines, with the cash component closing expected in the third quarter.
The cash element of $6.75 is 6.1% below Monday's closing price before any discount is applied. The total potential payment of $9.25 represents a 28.7% premium to the current share price.
Deal Outlook and Risks
Srinivas Rao, CEO of AtaiBeckley, noted that Lilly's expertise and reach are expected to accelerate development work. The transaction requires shareholder approval and antitrust clearance. The CVR may be transferred only in limited situations.
Risks include potential investor rejection of the merger, regulatory delays, or the CVR resulting in no payment. The CVR will not be listed on public markets. AtaiBeckley has no public events scheduled for this week, with attention shifting to the proxy statement and required approvals.
